asa glp 1 agonists GLP-1 RA guidance roundup 🔸 Should GLP-1 RAs be

These findings are supported by a previous study, reporting a reduction in PASI, despite not being statistically significant, together with substantial improvement of BMI and cholesterol levels in an open-label trial of liraglutide in obese PsO patients (59)

Willms, B

With continuing developments in the field of GLP-1 RA therapy, it is important for physicians to understand the benefits and practical use of GLP-1 RAs, as well as the clinical evidence, in order to achieve positive patient outcomes

Those patients who took GLP-1s had a higher survival rate after 10 years and were less likely to have tumors return compared to non-users

A reduction in neonatal growth was also seen when liraglutide was used during lactation without having been used during pregnancy ( Supplement 3 )

Although renin was discovered more than a century ago and the detection of angiotensin I, angiotensin II and aldosterone in the 50s allowed the definition of the classical RAAS pathway from 1961 (19), the research in this field continues and new evidence has recently emerged